Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia

{{article.zuoZheCn}}

PDF(1086 KB)
Frontiers of Medicine ›› 2022, Vol. 16 ›› Issue (1) : 139-149. DOI: 10.1007/s11684-021-0835-8

  • {{article.zuoZheCn}}
作者信息 +

Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia

  • {{article.zuoZheEn}}
Author information +
History +

本文亮点

{{article.highlightCn}}

Highlight

{{article.highlightEn}}

摘要

{{article.abstractCn}}

Abstract

{{article.abstractEn}}

作者总结

{{article.authorSummayCn}}

Author summay

{{article.authorSummayEn}}

关键词

Keywords

引用本文

导出引用
{{article.zuoZheCn_L}}. {{article.titleCn}}. {{journal.nameCn}}. 2022, 16(1): 139-149 https://doi.org/10.1007/s11684-021-0835-8

参考文献

参考文献

{{article.reference}}

版权

{{article.copyright.year}} {{article.copyright.holder}}
PDF(1086 KB)

Accesses

Citation

Detail

段落导航
相关文章

/